University of Pennsylvania returned for a series B round that boosted its immunotherapy spinout's overall funding to $231m.

Tmunity Therapeutics, a US-based immunotherapy spinout from University of Pennsylvania, completed a $75m series B round featuring the university yesterday.
Venture capital firm Andreessen Horowitz led the round, which included its own Cultural Leadership Fund in addition to antiviral drug producer Gilead Sciences and cell therapy services provider Be The Match BioTherapies, Westlake Village BioPartners and BrightEdge, American Cancer Society’s philanthropic impact vehicle.
Tmunity is working on immunotherapies for cancer, infectious and autoimmune diseases and will channel the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?